Review
CT and MR Imaging of the Adrenal Glands in Cortisol-secreting Tumors*
FRANCO LUMACHI1, PAOLO MARCHESI2, DIEGO MIOTTO3 and RAFFAELLA MOTTA3
Departments of 1Surgical and Gastroenterological Sciences, and
3Diagnostic Medical Sciences, University of Padua, School of Medicine, 35128 Padova, Italy;
2 Radiology Service, S. Antonio Hospital, 35128 Padova, Italy
Abstract. Cushing’s syndrome (CS), first described by the neurosurgeon Harvey Cushing in the 1930s, is the result of chronic glucocorticoid excess. In patients with adreno- corticotropic hormone (ACTH)-dependent CS, bilateral hyperplasia of the adrenal cortex occurs, while in those with ACTH-independent primary CS, either adrenocortical tumors or primary adrenal hyperplasia can be observed. Cortisol- secreting adrenocortical tumors are more frequently adenomas, while adrenal carcinoma accounts for only 5% of cases. Unfortunately, no reliable endocrinological tests are available and no specific tumor markers exist to differentiate between benign and malignant adrenal tumors, so both computed tomography (CT) and magnetic resonance (MR) imaging studies are currently required to localize and define adrenal lesions. Additional information to conventional imaging can be obtained using 18F-fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET)/CT, while percutaneous image-guided fine-needle aspiration cytology (FNAC) in some cases has shown a high accuracy in detecting malignancy and in confirming adrenal metastases. New PET tracers with selective affinity for the adrenal tissue are still under evaluation. Multidetector CT scan, with the combination of unenhanced and dynamic scans, represents the single most accurate modality for the detection and the characterization of adrenal adenomas. In these lesions, chemical-shift MR imaging produces a typical loss of signal intensity on out-of-
*Presented at the European Multidisciplinary Cancer Congress (ECCO 16), Stockholm, 23-27 September, 2011.
Correspondence to: Professor Franco Lumachi, University of Padua, School of Medicine, Department of Surgical & Gastroenterological Sciences, Via Giustiniani 2, 35128 Padova, Italy. Tel: +39 0498211812, Fax: +39 0498214394, e-mail: flumachi@unipd.it
Key Words: Adrenocortical tumors, Cushing’s syndrome, adrenal imaging, cancer, CT, MR, review.
phase breath-hold gradient-echo images in lipid-rich adenomas. For these lesions there is no difference between CT and MR imaging, while MR chemical shift imaging is very helpful in identifying the additional small group of adenomas where intracellular lipid content is minimal.
Cushing’s syndrome (CS), first described by the neurosurgeon Harvey Cushing in the 1930s, is the result of chronic glucocorticoid (i.e. cortisol) excess (1). Once iatrogenic causes and pseudo-Cushing’s states, such as chronic alcoholism, depression, or polycystic ovary syndrome, have been excluded and the diagnosis of primary hypercortisolism is confirmed, the second step should be to differentiate between adreno- corticotropic hormone (ACTH)-dependent and ACTH- independent CS. In patients with ACTH-dependent CS, bilateral hyperplasia of the adrenal cortex occurs, while in those with ACTH-independent ‘spontaneous’ CS, either adrenocortical tumors or primary adrenal hyperplasia can be observed (Figure 1). Cortisol-secreting adrenocortical tumors are more frequently adenomas, while adrenal carcinoma accounts for only 5% of cases of CS (2). Unfortunately, no reliable endocrinological tests are available and no specific tumor markers exist to differentiate between benign and malignant adrenal masses, so computed tomography (CT) and magnetic resonance (MR) imaging studies are currently required to localize and define adrenal lesions, although these techniques sometimes fail to characterize some small adrenal masses (3, 4). Additional information to conventional imaging can be obtained using 18F-fluoro-2-deoxyglucose (FDG)- positron-emission tomography (PET)/CT, where tumor/liver maximum standardized uptake values ratio can be helpful in cases of doubtful visual uptake (5). In some cases, percutaneous image-guided fine-needle aspiration cytology (FNAC), as well as 1311-6- ß-iodomethyl-norcholesterol scintigraphy, have shown high accuracy and were useful to confirm adrenal metastases or rare primary adrenal hyperplasia, in combination with CT and MR imaging (2, 6, 7).
Computed Tomography Scanning
In clinical practice, the adrenal glands can be well demonstrated with both single and multidetector CT scanners, using slice thickness 2.5-3 mm with 1.5-3 mm interval, before and after 100-150 ml of iodinated contrast administration. Usually, a portal venous phase (60-90 s) is preferred (8). Multidetector scanners offer higher performance, with collimation even smaller than 1 mm, allowing better multiplanar reconstructions (in coronal and sagittal planes), useful for depicting all anatomic relationships of the adrenal mass (9). On CT scan, normal adrenal glands appear symmetric and homogeneous, with a density approximately equal to that of the kidney (10). Adrenal adenomas usually appear relatively small (1-5 cm), round or ovoid, homogeneous, with smooth borders and lower than water density (<10 Hounsfield units [HU] without contrast), due to abundant intracellular lipid content (9-13). Two thirds of adenomas contain significant intracellular lipid and show the typical unenhanced CT attenuation <10 HU, while 25-30% of them are lipid-poor, with unenhanced CT attenuation >10 HU (10, 14, 15). Large adenomas may appear inhomogeneous, containing cystic degeneration, calcifications, hemorrhage and necrosis (15). On contrast-enhanced CT, performed 60 s and 15 min after intravenous contrast medium administration, adenomas show both a rapid enhancement and a rapid wash-out loss of contrast, while non-adenomas typically show a slower contrast washout phase (Figure 2). When the 15-min delay protocol is used, an absolute contrast wash- out of >60% and a relative contrast washout of >40% have 86-88% sensitivity and 92-98% specificity for the diagnosis of adenomas, respectively (9, 10, 12, 14). With the combination of unenhanced and dynamic scans, CT represents the single most accurate modality for detection and characterization of adrenal adenomas (9, 10).
Unfortunately, no differentiation can be made between cortisol-secreting adenomas and incidentally discovered nonfunctioning adrenal masses on the basis of imaging features alone (9, 11, 15). Imaging findings more suspicious of adrenal carcinomas are large lesion size (>4 cm), irregular or unclear margins, heterogeneous appearance and attenuation higher than 10 HU on unenhanced CT (9, 10, 14). On contrast-enhanced CT, adrenal carcinomas enhance avidly, with relative and absolute percentage washout of <40% and <60%, respectively, and exceptionally, they remain stable for more than 3-4 months (10, 14).
Magnetic Resonance Imaging
The appropriate MR imaging study protocol of adrenal glands should include (9): T1-weighted (T1w) gradient- recalled echo (GRE) sequences in- and out-of-phase, slice
thickness of 3-5 mm; T2-weighted (T2w) turbo spin-echo (TSE) sequences with fat suppression, slice thickness of 3- 5 mm and T2w half-Fourier acquisition single-shot turbo- spin-echo (HASTE) sequences, slice thickness of 5 mm. The use of breath-hold sequences mostly eliminates most motion artifacts (16). Intravenous gadolinium (Gd) administration allows the characterization of the vascular pattern of adrenal masses, like contrast-enhanced CT. Axial images are standard, while coronal and sagittal images may help in delineating large adrenal masses (9). On MR, normal adrenal glands show low to intermediate T1- and T2-signal intensity, equal to or slightly lower than that of the normal liver (11, 14). Adrenal adenomas usually appear homogeneous on all sequences, mostly isointense at T2w TSE sequences and slightly hypointense at T1w TSE sequences compared with the liver, and show moderate and relatively uniform enhancement on early Gd-enhanced images (17). Small areas of abnormal signal intensity within an adenoma may be due to cystic change, hemorrhage or necrotic foci (9, 14). Chemical-shift images (CSI), based on the physical property of fat protons that precess at a lower frequency than water protons, produces loss of signal intensity on out-of-phase breath-hold gradient-echo images in lipid-rich lesions, typical of adenomas (8) (Figure 3). The abundant intracellular lipid content characteristic of benign adrenal masses is responsible for the typical dropout of 40% at CSI (11, 17).
CSI is very helpful in identifying the additional small group of adenomas in which intracellular lipid content is minimal, whereas for lipid-rich adenomas, there is no particular difference between CT and MR imaging, since CT should be considered virtually 100% accurate for their detection (9, 10, 13, 14). Adrenal carcinomas are usually larger than adenomas, heterogeneous on both CT scan and MR imaging, due to areas of necrosis, hemorrhage and calcifications (10, 11). On MR, they appear large, heterogeneous, invasive and bright enhancing, with intermediate signal intensity at T2w TSE sequence, with nonhomogeneous vascularization pattern, and without decrease of signal intensity at opposed-phase imaging compared with in-phase imaging (9).
In conclusion, for all patients with CS, both CT and MR imaging are usually performed, especially when a differentiation between benign and malignant adrenal masses is required. In selected cases, when requested for surgical planning, image-guided FNAC may represent a safe and sensitive procedure. On 18F-FDG-PET and PET/CT, malignant lesions usually show a high uptake, while the uptake is in the range of hepatic activity for benign lesions (18). New PET tracers with selective affinity for the adrenal tissue, such as 11C-metomidate (MTO) and 18F-etomidate (FETO), are still under evaluation (19, 20).
: 53/78
Acq Tm: 15:31:20
or: A117.4
Portale
530×404
B301
a
b
C
Acq Tm: 16%
Pre
Acq Tm
a
b
C
a
b
C
·
References
1 Aron DC, Findling JW and Tyrrell JB: Glucocorticoids and adrenal androgens. In: Basic and Clinical Endocrinology. Greenspan FS and Gardner DG (eds.). New York, NY, Lange Medical Book/McGraw-Hill, pp. 334-376, 2001.
2 Lumachi F, Zucchetta P, Marzola MC, Bui F, Casarrubea G and Angelini F: Usefulness of CT-scan, MRI and radiocholesterol scintigraphy as adrenal imaging in Cushing’s syndrome. Nucl Med Commun 23: 469-473, 2002.
3 Lumachi F, Basso SM, Borsato S, Tregnaghi A, Zucchetta P, Marzola MC and Bui F: Role and cost-effectiveness of adrenal imaging and image-guided FNA cytology in the management of incidentally discovered adrenal tumours. Anticancer Res 25: 4559-4562, 2005.
4 Jhaveri KS, Wong F, Ghai S and Haider MA: Comparison of CT histogram analysis and chemical-shift MRI in the characterization of indeterminate adrenal nodules. AJR 187: 1303- 1308, 2006.
5 Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, Conte-Devolx B, Henry JF, Mundler O and Taïeb D: Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours? Eur J Nucl Med Mol Imaging 35: 2018-2025, 2008.
6 Lumachi F, Borsato S, Brandes AA, Boccagni P, Tregnaghi A and Angelini F: Fine-needle aspiration cytology of adrenal masses in noncancer patients. Cancer 93: 323-329, 2001.
7 Saeger W, Fassnacht M, Chita R, Prager G, Nies C, Lorenz K, Bärlehner E, Simon D, Niederle B, Beuschlein F, Allolio B and Reincke M: High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicentric trial in 220 consecutive patients. Human Pathol 34: 180-186, 2003.
8 Lumachi F, Zucchetta P, Cecchin D and Motta R: Imaging studies in Cushing’s syndrome. In: Advances in Medicine and Biology, vol. 23. Berhardt LV (eds.). Hippurage, NY, Nova Science Publishers, 2011.
9 Goldman SM and Kenney PJ: The adrenal glands. In: Computed Body Tomography with MRI Correlation, 4th ed. Lee JKT, Sagel SS and Stanley RJ (eds.) Philadelphia, PA, Lippincott Williams and Wilkins, pp. 1311-1373, 2006.
10 Ilias I, Sahdev A, Reznek RH, Grossman AB and Pacak K: The optimal imaging of adrenal tumors: a comparison of different methods. Endocrine Relat Cancer 14: 587-599, 2007.
11 Rockall AG, Babar SA, Sohaib SAA, Isidori AM, Diaz-Cano S, Monson JP, Grossman AB and Reznek RH: CT and MR imaging of the adrenal glands in ACTH-independent Cushing syndrome. Radiographics 24: 435-452, 2004.
12 Hennings J, Hellman P, Ahlstrom H and Sundin A: Computed tomography, magnetic resonance imaging and 11C-metomidate positron-emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 69: 314-322, 2009.
13 Yoh T, Hosono M, Komeya Y, Im SW, Ashikaga R and Shimono T: Quantitative evaluation of norcholesterol scintigrapy CT attenuation value and chemical-shift MR imaging for characterizing adrenal adenomas. Ann Nucl Med 22: 513-519, 2008.
14 Blake MA, Cronin CG and Boland GW: Adrenal imaging. Am J Roentgenol 194: 1450-1460, 2010.
15 Federle MP: Part III Genitourinay and Retroperitoneum. Section 3 Adrenal. In: Diagnostic Imaging. Abdomen. Salt Lake City, Amirsys Inc., pp. 2.02-2.38, 2004.
16 Ozturk E, Sildiroglu HO, Kantarci M, Doganay S, Güven F, Bozkurt M, Sonmez G and Cinar Basekim C: Computed tomography findings in diseases of the adrenal gland. Wien Klin Wochenschr 121: 372-381, 2009.
17 Burton SS and Ros PR: Adrenal Glands. In: Magnetic Resonance Imaging, 3rd ed. Stark DD and Bradley WG Jr (eds.). St. Louis, Mosby, pp. 503-516, 1999.
18 Becherer A, Vierhapper H, Pötzi C, Karanikas G, Kurtaran A, Schmaljohann J, Staudenherz A, Dudczak R and Kletter K: FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 16: 289-295, 2001.
19 Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R and Kletter K: Positron emission tomography imaging of adrenal masses: 18F- fluorodeoxyglucose and the 116-hydroxylase tracer 11C- metomidate. Eur J Nucl Med Mol Imaging 31: 1224-1230, 2004.
20 Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, Dudczak R, Kletter K and Karanikas G: [18F] FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 33: 669-672, 2006.
Received April 13, 2011
Revised June 6, 2011
Accepted June 13, 2011